May 5, 2026 | Pharma, healthcare, patient access
Integrated capabilities combining advanced analytics, pharmacy, and specialized talent to improve access, affordability, and adherence

Inizio announced the official launch of its fully integrated, end-to-end Hub Services, a cornerstone of its market-leading Patient Solutions offering. Delivered by Inizio Engage, the Inizio business unit specializing in patient engagement and support, this next-generation solution addresses the growing complexity of patient access, reimbursement, and adherence, while enabling clients to partner with a more agile, strategic, and outcome-driven organization.
As life sciences organizations navigate an increasingly dynamic policy and payer landscape, and higher expectations from patients, the need for more connected, patient-centric support models has never been greater. “Inizio Engage’s evolved Hub Services introduces a next-generation approach, integrating human expertise, intelligent technology, and pharmacy capabilities, supported by advanced analytics to simplify and accelerate the path to therapy,” said Ryan Quigley, CEO, Inizio. “This launch represents another opportunity for Inizio to lead the way as the global Intelligent Commercialization partner, bringing together insight, innovation, and execution to deliver more coordinated, patient-centered solutions for our clients.”
Read full article here.
This content was provided by Inizio
Latest Content from Inizio
Our best practice approach to tracking studies.
The remote exchange of data between patients and their clinician
Our client had previously conducted some research and knew that a large proportion of target patients also had addiction issues. They wanted to know more about addiction treatment pathways and…
Chronic pain is defined as pain lasting longer than 6 months and affects 100 million Americans. Living with Chronic Pain is a quantitative study conducted online amongst 390 US patients…
Published in eyeforpharma October 2016 by Marc Yates
Our client wanted to understand in detail the usage decision drivers, triggers and processes for a high-cost innovative Acute Heart Failure (AHF) drug used in the acute emergency setting in…
In association with PMGroup
Our client wanted to understand why uptake of HPV vaccination in the Asia-Pacific region was limited. In order to help increase uptake, they wanted to publish the market research findings…
Reflections on THET Conference 2016: Evidence, Effectiveness & Impact
Ulcerative Colitis (UC) is a progressive and debilitating disease which affects between 2.5 to 3 million people in Europe. Living with UC is a quantitative study conducted online amongst 325 patients, including…
